How promising is the idea of stem cells for MS? I have been working slowly as time permits on a piece more specifically about hematopoietic stem cell transplantation (HSCT) for MS. Two new pieces caught my eye on this topic so I’ll start with those. Stem cells for MS NurOwn Found Safe, Shows Promise in […]
Weekly reads: stem cells for MS, blood origins, iPSCs Read More »
The big news of the week was the big FDA stem cell in court by Judge Jesus Bernal here in California, who ruled in favor of a chain of stem cell clinics called Cell Surgical Network. The FDA had been seeking an injunction against the clinics. I believe the ruling was founded in part on
Weekly reads: CRISPR, FDA stem cell loss, pioneering AMD study, MS, Verve Therapeutics Read More »
As I’ve mentioned recently, it’s my busy time for medical school teaching and not long ago we did a GI lab that included one of my favorite structures in the course: taste buds. Taste buds The medical students seem fascinated with taste buds too. I can tell as their professor when something is particularly interesting
Weekly reads: taste buds, organoids, good news on CRISPR safety Read More »
I have a soft spot for fibroblasts, perhaps because one of the first immortalized cell lines I ever grew was NIH3T3. These are mouse fibroblasts that have been immortalized. They are very useful for a variety of experiments. I used them to study an oncogene called E2A-PBX1. Experience with fibroblasts including 3T3s I was amazed
Weekly reads: fibroblasts, gene-editing, Mitalipov, personhood, embryos Read More »
Cloning is one of those topics that both fascinates and kind of scares people, especially the idea of duplicating people. I regularly cover the topic here on The Niche because stem cell technologies are involved. Also, one form of the process sometimes called “therapeutic cloning” involves embryonic stem cells. Duplicating mammals has now long been
Weekly reads: freeze-dried cloning, FDA signals, stem cell escapees Read More »
The last six months I’ve been spending even more time than usual writing NIH grants (and a few others). The last two weeks have been especially busy on this front as I am getting an R01 renewal out the door. My paper reading lately has been mostly related to the grant writing I’m doing. Still,
Weekly reads: NIH grants, side effect of darker hair, FDA warning, CRISPR Read More »
It’s been mostly a downbeat week on the stem cell news front including a deep revisit by Reuters to the Piero Anversa case that has new revelations. It’s ugly stuff involving other folks too. We’ll start on the iPS cell front, where a trial participant had a teratoma. I’ve had a long-standing interest in the
People are the real driving force in the stem cell and regenerative medicine field including my colleague Jan Nolta here at UC Davis. She is the Director of our Stem Cell Program. There’s also news about Stanford’s stem cell Director Irv Weissman. Jan Nolta receives award Jan’s lab is prolific and in many ways is
Weekly reads: Jan Nolta recognition, new director after Irv, FDA guidance Read More »
I recently wrote about stem cell-related ideas for anti-aging and even cheating death, but there are of course other approaches including drugs like metformin. A new article outlines a massive research funding plan to tackle aging. Let’s start with that. Recommend reads including anti-aging Saudi Arabia plans to spend $1 billion a year discovering treatments to
Weekly reads: $1B Saudi anti-aging push, OCT4 necklace, cancer trial wows, coffee brain Read More »
There’s nothing quite like getting a new paper out as a scientist running a research lab so this week we can celebrate our new pediatric brain tumor study. I’ll start the weekly reads with that paper. Of course, getting new grants is amazing too but there’s more of a feel of completion after a paper
Weekly reads: our new brain tumor paper, levitation, dear doctor, Japan, more Read More »